

VYVGART[®] Hytrulo

(efgartigimod alfa and
hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

In-Office Subcutaneous Injection Guide

VYVGART Hytrulo is a subcutaneous injection delivered into the layer beneath the skin. It usually takes 30 to 90 seconds to inject and is given at an infusion center, doctor's office, or at home.*†


Get information about what to expect for the in-office injection process: before, during, and after.

*For at least 30 minutes after your injection, a healthcare professional will monitor you for reactions.

†In some cases, VYVGART Hytrulo may also be given at home by a trained nurse.

VYVGART Hytrulo is injected in treatment cycles with an individualized break between cycles*

A treatment cycle consists of 1 injection each week for 4 weeks (4 injections per cycle)



Breaks between cycles are individualized because your next cycle of treatment is based on an evaluation of your generalized myasthenia gravis (gMG) symptoms and side effects by your neurologist.* Track your symptoms to help your neurologist determine your next treatment cycle. The safety of starting the next treatment cycle sooner than 4 weeks from the last injection of the previous treatment cycle has not been established.

*If additional cycles are needed.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART HYTRULO for subcutaneous injection](#).

BEFORE YOUR INJECTION

VYVGART® Hytrulo

(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

THE DAY BEFORE YOUR SUBCUTANEOUS INJECTION, YOU MAY WANT TO:

- Prepare for your visit. You may need to find a ride if you can't drive yourself, and you should plan to get to your appointment at least 15 minutes early
- Consider wearing clothing that's loose around the waist on the day of your injection
- Bring a list of your current medications to bring to your appointment

KEEP IN MIND: HOW TO PASS THE TIME

VYVGART Hytrulo usually takes 30 to 90 seconds to inject, but your healthcare provider will monitor you for reactions for at least 30 minutes after your injection. You may want to bring something to do while you wait.



Book



Crossword



TV show



Podcast



Game

SELECT IMPORTANT SAFETY INFORMATION

More patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts. The majority of infections and observed lower white blood cell counts were mild to moderate in severity. Your healthcare provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART HYTRULO.

Please see Important Safety Information throughout. Please see full Prescribing Information for VYVGART HYTRULO for subcutaneous injection.

THE 5 STEPS OF YOUR VYVGART Hytrulo SUBCUTANEOUS INJECTION

01 | Check in

Once you get to your treatment location, check in with the staff and confirm your insurance information.

02 | Get ready for injection

An office staff member will help get you ready for your subcutaneous injection. VYVGART Hytrulo may also be prepared for injection at this time.

03 | Receive your injection

A healthcare professional will inject VYVGART Hytrulo subcutaneously into an area of pinched skin on your abdomen over 30 to 90 seconds. A different area of your abdomen will be used for subsequent injections of VYVGART Hytrulo.

04 | Stay for monitoring

You will be monitored for injection site reactions and other side effects for at least 30 minutes after your injection. Consider bringing something to pass the time.

05 | Check out

Before you leave, make sure to confirm or schedule your next appointment. If this is the last injection of your treatment cycle, you may want to have a plan in place with your doctor for symptom tracking.



Not actual size

**AFTER STARTING VYVGART Hytrulo, TRACK YOUR SYMPTOMS
EACH WEEK AND KEEP YOUR NEUROLOGIST UP TO DATE**



Scan the QR code or visit [gMGSymptomTracker.com](https://www.gmsymptomtracker.com)
to find a symptom tracking tool that may help with
your VYVGART Hytrulo journey.

ARE YOU ENROLLED IN THE VYVGART PATIENT SUPPORT PROGRAM?

My VYVGART® *Path*

With My VYVGART Path, a Nurse Case Manager is waiting to help you throughout your VYVGART Hytrulo treatment journey. **Talk with your doctor** and ask to be enrolled in My VYVGART Path, or visit [MyVYVGARTPath.com](https://www.MyVYVGARTPath.com) to **download the form**.

Already enrolled? Reach out to a Nurse Case Manager
for support at **1-833-MY-PATH-1** (1-833-697-2841).

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO and efgartigimod alfa-fcab can cause the immune system to have undesirable reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART HYTRULO for subcutaneous injection](#).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO may cause serious side effects, including:

- **Infection.** VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. More patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts. The majority of infections and observed lower white blood cell counts were mild to moderate in severity. Your healthcare provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART HYTRULO. Tell your healthcare provider if you have any history of infections. Tell your healthcare provider right away if you have signs or symptoms of an infection during treatment with VYVGART HYTRULO such as fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. If a serious infection occurs, your doctor will treat your infection and may even stop your VYVGART HYTRULO treatment until the infection has resolved.
- **Undesirable immune reactions (hypersensitivity reactions).** VYVGART HYTRULO and efgartigimod alfa-fcab can cause the immune system to have undesirable reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. In clinical studies, the reactions were mild or moderate and occurred within 1 hour to 3 weeks of administration, and the reactions did not lead to VYVGART HYTRULO discontinuation. Your healthcare provider should monitor you during and after treatment and discontinue VYVGART HYTRULO if needed. Tell your healthcare provider immediately about any undesirable reactions to VYVGART HYTRULO.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

- Have a history of infection or you think you have an infection.
- Have received or are scheduled to receive a vaccine (immunization). Discuss with your healthcare provider whether you need to receive age-appropriate immunizations before initiation of a new treatment cycle with VYVGART HYTRULO. The use of vaccines during VYVGART HYTRULO treatment has not been studied, and the safety with live or live-attenuated vaccines is unknown. Administration of live or live-attenuated vaccines is not recommended during treatment with VYVGART HYTRULO.
- Are pregnant or plan to become pregnant and are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the common side effects of VYVGART HYTRULO?

The most common side effects of efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects of VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART HYTRULO?

VYVGART HYTRULO is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see the full Prescribing Information for [VYVGART HYTRULO](#) and talk to your doctor.